Baricitinib (INCB28050, LY3009104)
Inquiry
| Post Date: | Apr 03,2015 |
| Expiry Date: | Apr 02,2016 |
| Detailed Description: |
Cas No. :1187594-09-7
Quantity: 50g Specs:98% purity Payment Method: T/T, Western Union Baricitinib is an orally administered selective JAK1 and JAK2 inhibitor that is JAK3-sparing. Currently, baricitinib is in Phase II development as a treatment for rheumatoid arthritis and psoriasis. |
| CAS Registry Number: | 1187594-09-7 |
| Synonyms: | ;2-(3-(4-(7H-Pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile;1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile;LY3009104;INCB028050; |
| Molecular Formula: | C16H17N7O2S |
| Molecular Weight: | 371.41668 |
| Molecular Structure: | 
|
| Company: | Shanghai Sun-shineChemical Technology Co.,Ltd. [ China ] |
| Contact: | Rosie |
| Tel: | +86-027-59253327 |
| Fax: | 0086-27-5925 3326 |
| Email: | sales02@sun-shinechem.com |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.
